1992
DOI: 10.1073/pnas.89.17.7934
|View full text |Cite
|
Sign up to set email alerts
|

Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle.

Abstract: Complexes containing plasmid DNA, transferrin-polylysine conjugates, and polylysine-conjugated peptides derived from the N-terminal sequence of the influenza virus hemagglutinin subunit HA-2 have been used for the transfer of luciferase or -galactosidase marker genes to K562 cells, HeLa cells, and BNL CL.2 hepatocytes. These DNA complexes mimic the entry of viruses into cells, as they contain functions for (i) the packaging of the nucleic acid with polylysine, (i) the attachment to the cell and receptor-mediat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

8
337
1
3

Year Published

1993
1993
2006
2006

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 641 publications
(349 citation statements)
references
References 32 publications
8
337
1
3
Order By: Relevance
“…The latter has previously been shown to facilitate DNA delivery by poly-l-lysine based molecular conjugates. [11][12][13] A fusigenic liposome with a viral fusion protein for gene delivery was recently constructed by fusion of UVinactivated Sendai virus with DNA/cationic lipid vesicles. 32 However, the application of an inactivated virus raises safety concerns regarding application for gene therapy.…”
Section: Nmol) Were Mixed With Increasing Amounts Of Virosomes Contaimentioning
confidence: 99%
See 1 more Smart Citation
“…The latter has previously been shown to facilitate DNA delivery by poly-l-lysine based molecular conjugates. [11][12][13] A fusigenic liposome with a viral fusion protein for gene delivery was recently constructed by fusion of UVinactivated Sendai virus with DNA/cationic lipid vesicles. 32 However, the application of an inactivated virus raises safety concerns regarding application for gene therapy.…”
Section: Nmol) Were Mixed With Increasing Amounts Of Virosomes Contaimentioning
confidence: 99%
“…9,4,10 For the latter the membrane-destabilizing properties of the fusion peptide from hemagglutinin was employed. [11][12][13] Hemagglutinin (HA), the membrane fusion protein of influenza virus mediating viral cell entry, is composed of two membrane subunits, HA1 and HA2. [14][15][16] The virus binds to cells through interaction of the HA1 subunits with sialylated lipids (gangliosides) or proteins in the membrane of target cells.…”
Section: Introductionmentioning
confidence: 99%
“…1,2 In addition, the simple conjugation of a targeting moiety to nonviral gene carrier can facilitate tissue-targeting gene delivery. [3][4][5][6][7][8][9][10][11][12][13] To use it for cardiovascular disease gene therapy, we have developed a new gene carrier system, TerplexD-NA. [14][15][16][17][18] TerplexDNA is composed of plasmid DNA (pDNA), stearyl-poly-L-lysine (stearyl-PLL), and lowdensity lipoprotein (LDL).…”
Section: Introductionmentioning
confidence: 99%
“…(Ren et al, 2004), recombinant cross-packaging of adeno-associated virus (Aikawa et al, 2002;Li et al, 2003), and lentivirus (Sakoda et al, 2003) have been the choice for gene delivery to cardiomyocytes because of their high efficiency, but they are immunogenic and may raise risk to patients (Mulligan, 1993). Compared with viral vectors, synthetic polymers have the advantages of no specific immunogenecity, low risk, and ease of large-scale production, and thus have been considered as a potential alternative to viral vectors (Nishikawa and Huang, 2001;Templeton and Lasic, 1999;Wagner et al, 1992). However, so far there is little study on polymer mediated gene delivery to cardiomyocytes.…”
Section: Introductionmentioning
confidence: 99%